GLP-1 Compound Regulatory Landscape 2025: What Researchers Need to Know

The regulatory situation surrounding GLP-1 class compounds changed significantly in 2024 and continued to develop into 2025. For anyone engaged in research procurement in this space, understanding what the FDA has done, what is now restricted, and where legal gray areas remain is not optional — it is foundational to responsible sourcing.

The 2024 Shortage List Removal

The pivotal regulatory event was the FDA's decision to remove semaglutide and tirzepatide from its official drug shortage list. Semaglutide (the active ingredient in Ozempic and Wegovy) was removed from the shortage list in October 2024. Tirzepatide (the active ingredient in Mounjaro and Zepbound) followed in early 2025.

This matters because the legal basis for much of the compounding pharmacy market in GLP-1 class molecules rested directly on shortage status. Under the Federal Food, Drug, and Cosmetic Act, compounding pharmacies — both 503A pharmacies serving individual patients and 503B outsourcing facilities serving healthcare providers — are permitted to compound copies of FDA-approved drugs when those drugs appear on the official shortage list. Once that shortage designation is lifted, the legal basis for compounding those specific molecules narrows considerably.

The FDA issued guidance and a compliance policy in late 2024 stating that 503B outsourcing facilities had a transition period to wind down bulk compounding of semaglutide and tirzepatide. Enforcement timelines were adjusted multiple times, with final compliance deadlines for most 503B facilities set during the first half of 2025.

What This Means for Compounding Pharmacies

503A pharmacies — the type that compounds medications for individual patients based on a specific prescription — faced a separate but related set of restrictions. The FDA position was that once a drug is no longer in shortage, compounding pharmacies cannot produce it in bulk or for general distribution. Individual patient compounding with documented medical necessity has remained in a more ambiguous position, and some healthcare providers and compounding pharmacies have continued operating on that basis while litigation plays out.

Several compounding pharmacy trade organizations filed legal challenges to the FDA's shortage removal decisions and enforcement timelines. As of early 2025, federal court proceedings in multiple jurisdictions were ongoing. The legal landscape was not fully settled, and individual rulings had temporarily stayed enforcement in some cases before being reversed or appealed.

The practical outcome for patients who had been using compounded semaglutide or tirzepatide from compounding pharmacies was disruption to supply chains and in many cases transition back to branded pharmaceutical products, where availability had improved substantially since the height of the shortage.

The Research Compound Market: A Different Category

Research-grade GLP-1 class compounds occupy a legally distinct category from pharmaceutical and compounding pharmacy products. Research compounds are sold explicitly for laboratory and scientific research purposes and are not intended for human administration. This distinction matters legally, but it does not resolve all ambiguities.

The FDA regulates drugs — substances intended to diagnose, treat, cure, or prevent disease in humans or animals. A compound sold strictly for research purposes, clearly labeled as not for human use, and transacted without claims of medical efficacy operates in a different regulatory framework than a compounding pharmacy producing doses for patient administration. Research compound suppliers are subject to regulations around proper labeling, they cannot make health claims, and they may be subject to DEA scheduling requirements where applicable.

However, the de facto use of research-grade GLP-1 compounds by individuals — which is widely documented — places those transactions in an area regulators have been paying increasing attention to. The FDA has issued warning letters to specific research compound suppliers who made explicit human-use claims or marketed in ways that implied medical intent.

The Sourcing Distinction That Matters

The cleanest way to characterize the three categories is: pharmaceutical (FDA-approved, manufactured under cGMP, dispensed by licensed pharmacies); compounded (prepared by licensed pharmacies under 503A or 503B frameworks, with documented patient-specific or facility needs); and research-grade (sold for laboratory research, not for human administration, manufactured under quality standards that vary significantly by supplier).

For researchers operating in legitimate laboratory or preclinical research contexts, research-grade sourcing may be appropriate when pharmaceutical or clinical-grade supply is unavailable or cost-prohibitive for the research purpose. The critical variable in research-grade sourcing is quality verification — third-party tested purity and identity confirmation — since research-grade supply chains are not subject to the cGMP manufacturing standards that govern pharmaceutical production.

The regulatory situation in this space is evolving. What was permissible under shortage conditions in 2023 is not necessarily permissible under post-shortage conditions in 2025. Researchers and individuals engaging with GLP-1 class compounds in any capacity should track FDA enforcement actions, consult qualified legal and medical counsel, and not rely on supplier representations alone to determine compliance.

Disclaimer: This content is for informational purposes only. These compounds are not approved by the FDA for human use. Always consult a qualified healthcare professional before considering any research compound.